Nordicus Partners Corporation has announced the formation of NoviThera Aps to develop a Monoclonal antibody for psoriasis treatment. Psoriasis is an immune-mediated inflammatory disease treated with topical creams and antibodies. NoviThera aims to create a unique treatment to cure or prevent psoriasis. The company acquired the invention from Alteral Therapeutics in Denmark and appointed Allan Wehnert as CEO. Research will focus on developing a human rat model to test the treatment. Nordicus Partners Corporation specializes in supporting Nordic life sciences companies and recently acquired two Danish biotech firms.

Read more at GlobeNewswire: Nordicus Partners Corporation Announces The Formation Of A